Search IPSC
Century Therapeutics, Inc.
Nasdaq · CIK 1850119
Last close1.53
Daily change-0.08 (-4.97%)
10 Years gain-93.30%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IPSC · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
54.5Momentum
100.0Acceleration
100.0Confidence
74.0Annual Revenue4
Quarterly Revenue11
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet12.1 / 15
Shareholder Economics2.2 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 4724.5781 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 38.4314%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM3,823.67%OK
Revenue CAGR 3Y175.88%OK
Gross Margin100%OK
Operating Margin-27.12%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-54.71%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO1.32xOK
Diluted Share Growth 1Y38.43%OK
SBC / Revenue10.36%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $109.16M | $109.16M | -$17.27M | -$103.88M | -$104.72M | 100% | -15.82% | -95.93% | -196.41% | 86.56M |
| 2025 FY Dec 31, 2024 | $6.59M | $6.59M | -$138.14M | -$110.14M | -$110.29M | 100% | -2,096.48% | -1,673.84% | n/a | 78.65M |
| 2024 FY Dec 31, 2023 | $2.24M | $2.24M | -$146.55M | -$88.35M | -$102.08M | 100% | -6,556.87% | -4,567.52% | -2,400.15% | 59.31M |
| 2023 FY Dec 31, 2022 | $5.20M | $5.20M | -$133.83M | $14.05M | -$16.55M | 100% | -2,574.17% | -318.37% | -116.57% | 32.39M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$94.88M | -$89.00M | -$133.97M | n/a | n/a | n/a | -1,335.55% | 32.39M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $110.73M | sum latest 4 fiscal quarters Revenue | OK | 0001558370-25-011575, 0001104659-25-110851 |
| Revenue Growth TTM | 3,823.67% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001558370-25-011575, 0001104659-25-110851 |
| Revenue CAGR 3Y | 175.88% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-026759 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001104659-26-026759 |
| Gross Profit CAGR 3Y | 175.88% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-026759 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001558370-25-011575, 0001104659-25-110851 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001558370-25-011575, 0001104659-25-110851 |
| Operating Margin | -27.12% | Operating Income / Revenue | OK | 0001558370-25-011575, 0001104659-25-110851 |
| ROIC | -54.71% | NOPAT / Average Invested Capital | OK | 0001558370-25-011575, 0001104659-25-110851 |
| Net Debt / CFO | 1.32x | Net Debt / CFO | OK | 0001558370-25-011575, 0001558370-25-007885 |
| Current Ratio | 10.72x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 10.36% | SBC / Revenue | OK | 0001558370-25-011575, 0001558370-25-007885 |
| Revenue per Diluted Share | $1.28 | Revenue / Diluted Shares | OK | 0001558370-25-011575, 0001104659-25-110851 |